SNBL USA is in a unique position to perform ARS studies, from demonstration of efficacy in representative animal models, to pivotal nonclinical studies under the FDA’s Animal Rule.
We are proud of SNBL’s long history of excellence and leadership across our multiple product and service offerings; but more importantly, we benchmark our true success by what we achieve for our customers today and what we do to enable a better future for patients and their families tomorrow.Read More
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. With its multiple worldwide facilities and countless skilled and experienced scientists and technicians, SNBL Group works together in providing a full range of drug development services.
As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.
Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.
Sho Watanabe, SNBL USA Study Director, is scheduled to present a poster with results to support use of inracerebroventricular (ICV) for repeat drug administration in cynomolgus monkeys. Visit SNBL USA team members at The Society of Toxicology’s 55th Annual Meeting and ToxExpo at Booth #1409Read More
SNBL USA has recently received continued full accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) for its animal programs at both SNBL USA in Everett, WA and SNBL USA Scientific Resource Center (SRC) in Alice, TX.Read More
Today, it is our privilege to pay tribute to all of America’s veterans. Your patriotism, love of country, and sense of duty allows us to sleep safe and free at night. We appreciate you for your service and honor you for all of your sacrifices. Thank you.Read More